Food Effect and Formulation Bioavailability Study of Vamifeport

Phase 1, randomised, open-label trial of vamifeport in beta thalassemia and sickle cell disease (SCD) (4 arms), sponsored by CSL Vifor. Primary endpoints: Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration at Day 13, Area under the plasma concentration versus time curve from time 0 extrapolated to infinite time at Day 13 and 1 more. Started Oct 2021; status: completed.